

## Order form



457 slides to better...

... Know – Understand – Plan – Decide

This new **updated** and **enriched** edition offers you in a clear, precise and concise format:

1. A review of the **worldwide pharma market**
2. A **presentation** of the **French healthcare system** and of the **latest measures** introduced by **health authorities**
3. An **analysis** of the **position** of the various **stakeholders**
4. An **assessment** of their **behavioral trends** by **2029**
5. An **estimate** of the **impact** of this evolution on the **market** and on **pharma companies' strategies** by **2029**

## Order form

### The French Pharma Market 2024 – 2029 Strategic Implications for Pharma Companies

- ☐ I wish to purchase a PowerPoint version of this report (457 slides) in English at a price of € 10,000 (excl. taxes), including:
  - An e-workshop meeting of ~2 hours (possibility of face-to-face workshop in Paris area)
  - A free access\* for all collaborators of the pharma group
- ☐ I pay Smart Pharma Consulting by bank transfer to:  
Société Générale – IBAN : FR76 3000 3027 4100 0200 1061 171  
SWIFT: SOGEFRPP

Fill out and send your order form to:

Email : [jmpeny@smart-pharma.com](mailto:jmpeny@smart-pharma.com) – Tel. : +33 6 11 96 33 78

Smart Pharma Consulting - 38, avenue Félix Faure – 75015 Paris – France

The report will be sent to you with an invoice by e-mail to:

Last name: _____	First name: _____
Function: _____	Company: _____
Address: _____	Zip code: _____
City: _____	Country: _____
E-mail: _____	Phone: _____

\* **Unlimited use** within the different **legal entities** of the group having purchased this report. It is permitted to save this report only on computers and hard drives belonging to the legal entity. This report can be disseminated to the legal entity employees only


## The French Pharma Market 2024 – 2029

### Strategic Implications for Pharma Companies

*“A rigorous analysis of the facts to support the strategic thinking of pharmaceutical companies”*

457 illustrated slides

Contents



## Introduction

### 1. Worldwide market overview

- 1.1. Healthcare expenditure
- 1.2. Pharma market attractiveness
- 1.3. Pharma R&D trends

- 1.4. Pharma companies' strategies
- 1.5. Synthesis

### 2. French healthcare system

- 2.1. Key stakeholders
- 2.2. Policy makers: Government – ARS – ANSM – HAS – CEPS
- 2.3. Payers
- 2.4. Providers: Territorial organization – HCPs – Healthcare facilities – Drug suppliers – Consumers / Patients
- 2.5. Expenditure & regulation
- 2.6. Synthesis

### 3. French pharma market

- 3.1. Structure and dynamics
- 3.2. Orphan drugs segment
- 3.3. Generics segment
- 3.4. Biosimilars segment

- 3.5. OTC segment
- 3.6. Market forecasts
- 3.7. Synthesis

### 4. Strategic priorities for pharma companies

- 4.1. Methodology
- 4.2. Stakeholders mapping
- 4.3. Policy makers & Payers
- 4.4. Physicians

- 4.5. Pharmacists
- 4.6. Patients & PAGs
- 4.7. Pharma competitors

Executive Summary: Strategic implications for pharma companies

Glossary